Lutathera Approval History
- FDA approved: Yes (First approved January 26, 2018)
- Brand name: Lutathera
- Generic name: lutetium Lu 177 dotatate
- Dosage form: Injection
- Company: Advanced Accelerator Applications S.A.
- Treatment for: Gastroenteropancreatic Neuroendocrine Tumors
Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Development History and FDA Approval Process for Lutathera
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.